Institutional shares held 132 Million
551K calls
47.1K puts
Total value of holdings $1.11B
$4.66M calls
$397K puts
Market Cap $734M
86,820,096 Shares Out.
Institutional ownership 151.83%
# of Institutions 191


Latest Institutional Activity in WVE

Top Purchases

Q2 2025
Adage Capital Partners Gp, L.L.C. Shares Held: 15M ($127M)
Q2 2025
Price T Rowe Associates Inc Shares Held: 5.19M ($43.9M)
Q2 2025
Loomis Sayles & CO L P Shares Held: 3.3M ($27.8M)
Q2 2025
Stem Point Capital LP Shares Held: 900K ($7.61M)
Q2 2025
Millennium Management LLC Shares Held: 692K ($5.85M)

Top Sells

Q2 2025
Kynam Capital Management, LP Shares Held: 4.56M ($38.5M)
Q2 2025
Twinbeech Capital LP Shares Held: 164K ($1.38M)
Q2 2025
Verition Fund Management LLC Shares Held: 52.7K ($446K)
Q2 2025
Wells Fargo & Company Shares Held: 125K ($1.05M)
Q2 2025
Voloridge Investment Management, LLC Shares Held: 683K ($5.77M)

About WVE

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.


Insider Transactions at WVE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
3.96M Shares
From 19 Insiders
Open market or private purchase 2.79M shares
Grant, award, or other acquisition 339K shares
Exercise of conversion of derivative security 824K shares
Sell / Disposition
727K Shares
From 7 Insiders
Open market or private sale 727K shares

Track Institutional and Insider Activities on WVE

Follow Wave Life Sciences Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells WVE shares.

Notify only if

Insider Trading

Get notified when an Wave Life Sciences Ltd. insider buys or sells WVE shares.

Notify only if

News

Receive news related to Wave Life Sciences Ltd.

Track Activities on WVE